Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS SE & CO. KGAA

(FRE)
  Report
Delayed Quote. Delayed Xetra - 10/22 11:35:26 am
41.015 EUR   -0.50%
10/21FRESENIUS SE : Barclays reaffirms its Buy rating
MD
10/18European ADRs Move Lower in Monday Trading
MT
10/07FRESENIUS SE : NorldLB gives a Buy rating
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
40.78(c) 40.65(c) 40.785(c) 41.22(c) 41.015(c) Last
894 119 624 069 911 376 1 036 432 731 351 Volume
-0.29% -0.32% +0.33% +1.07% -0.50% Change
More quotes
Estimated financial data (e)
Sales 2021 37 435 M 43 585 M 43 585 M
Net income 2021 1 824 M 2 124 M 2 124 M
Net Debt 2021 22 797 M 26 543 M 26 543 M
P/E ratio 2021 12,6x
Yield 2021 2,09%
Sales 2022 39 512 M 46 004 M 46 004 M
Net income 2022 2 067 M 2 406 M 2 406 M
Net Debt 2022 20 296 M 23 630 M 23 630 M
P/E ratio 2022 11,1x
Yield 2022 2,30%
Capitalization 22 888 M 26 623 M 26 649 M
EV / Sales 2021 1,22x
EV / Sales 2022 1,09x
Nbr of Employees 312 734
Free-Float 73,1%
More Financials
Company
Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion... 
More about the company
Ratings of Fresenius SE & Co. KGaA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about FRESENIUS SE & CO. KGAA
10/21FRESENIUS SE : Barclays reaffirms its Buy rating
MD
10/18European ADRs Move Lower in Monday Trading
MT
10/07FRESENIUS SE : NorldLB gives a Buy rating
MD
10/05FRESENIUS SE : Barclays maintains a Buy rating
MD
10/04FRESENIUS : Medical Care donates 250,000 euros to UNICEF – battle against COVID-19 p..
PU
09/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the German Securiti..
DJ
09/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the WpHG [the Ge..
DJ
09/27VIFOR PHARMA : Gets Japanese Marketing Authorization For Avacopan in Autoimmune Kidney Dis..
MT
09/23European ADRs Move Sharply Higher in Thursday Trading
MT
09/23FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section 1 of the W..
DJ
09/22FRESENIUS SE : Berenberg reaffirms its Buy rating
MD
09/22FRESENIUS SE : Gets a Buy rating from Goldman Sachs
MD
09/21FRESENIUS SE : DZ Bank reaffirms its Buy rating
MD
09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
DJ
09/17FRESENIUS : Bank of America – Global Healthcare Conference (PDF, 5.96 MB)
PU
More news
News in other languages on FRESENIUS SE & CO. KGAA
10/22WOCHENVORSCHAU/1. bis 7. November (44. KW)
10/205G-FUNK AN KLINKEN :  Echtzeit-Datenübertragung soll Patienten helfen
10/18Les ADR européens en baisse lundi
10/14FRESENIUS : Kabi verbessert über Kooperation die Versorgung von US-Patienten mit wichtigen..
10/05DGAP-NEWS : Novartis Pharma GmbH: Digitaler Gesundheitspreis für innovative E-Health-Proje..
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | FRE | DE0005785604 | MarketScreener
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 41,02 €
Average target price 49,40 €
Spread / Average Target 20,4%
EPS Revisions
Managers and Directors
Stephan Sturm President & Chief Executive Officer
Rachel Clare Empey Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Sebastian Biedenkopf Legal, Compliance & Human Resources Director
Klaus-Peter Müller Independent Member-Supervisory Board